VIP and neuroblastoma: Vasoactive intestinal peptide (VIP) significantly reduces MYCN expression in neuroblastoma cells (SH-SY5Y/IMR-32) and exhibits a synergistic inhibitory effect when combined with RA (Chevrier et al., 2008).